170 results on '"Lenting, Peter J."'
Search Results
2. Plasmin-cleaved von Willebrand factor as a biomarker for microvascular thrombosis
3. Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor
4. Type 2N von Willebrand disease: genotype drives different bleeding phenotypes and treatment needs
5. How unique structural adaptations support and coordinate the complex function of von Willebrand factor
6. Angiopoietin-2 binds to multiple interactive sites within von Willebrand factor
7. Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy
8. Efficacy of platelet-inspired hemostatic nanoparticles on bleeding in von Willebrand disease murine models
9. Antithrombin lowering in hemophilia: a closer look at fitusiran
10. A reactive center loop–based prediction platform to enhance the design of therapeutic SERPINs
11. A nanobody against the VWF A3 domain detects ADAMTS13-induced proteolysis in congenital and acquired VWD
12. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab
13. Antithrombotic potential of a single‐domain antibody enhancing the activated protein C‐cofactor activity of protein S
14. Osteoprotegerin modulates platelet adhesion to von Willebrand factor during release from endothelial cells
15. Microlyse: a thrombolytic agent that targets VWF for clearance of microvascular thrombosis
16. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID‐19
17. Camelid‐derived single‐chain antibodies in hemostasis: Mechanistic, diagnostic, and therapeutic applications
18. The Role of Platelets and von Willebrand Factor in the Procoagulant Phenotype of Inflammatory Bowel Disease.
19. Development and characterization of single‐domain antibodies neutralizing protease nexin‐1 as tools to increase thrombin generation
20. Laboratory monitoring of hemophilia A treatments: new challenges
21. A single‐domain antibody that blocks factor VIIa activity in the absence but not presence of tissue factor
22. Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia
23. von Willebrand Factor and Management of Heart Valve Disease: JACC Review Topic of the Week
24. Structure and dynamics of the platelet integrin-binding C4 domain of von Willebrand factor
25. Real-Time Monitoring of von Willebrand Factor in the Catheterization Laboratory: The Seatbelt of Mini-Invasive Transcatheter Aortic Valve Replacement?
26. Arterial Pulsatility and Circulating von Willebrand Factor in Patients on Mechanical Circulatory Support
27. Ex vivo editing of human hematopoietic stem cells for erythroid expression of therapeutic proteins
28. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
29. Complex formation with pentraxin-2 regulates factor X plasma levels and macrophage interactions
30. Shear Force-Induced Platelet Clearance Is a New Mechanism of Thrombocytopenia.
31. Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A
32. Macrophage receptor SR-AI is crucial to maintain normal plasma levels of coagulation factor X
33. von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends
34. von Willebrand Factor for Aortic Valve Intervention: From Bench to Real-Time Bedside Assessment
35. Transient von Willebrand factor‐mediated platelet influx stimulates liver regeneration after partial hepatectomy in mice
36. Accelerated uptake of VWF/platelet complexes in macrophages contributes to VWD type 2B–associated thrombocytopenia
37. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
38. Mutations in the A3 domain of Von Willebrand factor inducing combined qualitative and quantitative defects in the protein
39. Emerging Therapeutic Strategies in the Treatment of Hemophilia A
40. A murine model to characterize the antithrombotic effect of molecules targeting human von Willebrand factor
41. Macrophage LRP1 contributes to the clearance of von Willebrand factor
42. Factor VIII Accelerates Proteolytic Cleavage of von Willebrand Factor by ADAMTS13
43. Thrombocytopenia and Release of Activated von Willebrand Factor during Early Plasmodium falciparum Malaria
44. Von Willebrand factor mutation promotes thrombocytopathy by inhibiting integrin αllbβ3
45. Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B
46. A novel binding site for ADAMTS13 constitutively exposed on the surface of globular VWF
47. Clinical and molecular predictors of thrombocytopenia and risk of bleeding in patients with von Willebrand disease type 2B: a cohort study of 67 patients
48. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo
49. Altered thrombus formation in von Willebrand factor–deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa
50. Towards novel treatment options in von Willebrand disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.